The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.
A. Aguilar-Mahecha
No relevant relationships to disclose
M. Basik
No relevant relationships to disclose
J. W. Chapman
No relevant relationships to disclose
K. Jahan
No relevant relationships to disclose
S. Hassan
No relevant relationships to disclose
L. Zhu
No relevant relationships to disclose
C. F. Wilson
No relevant relationships to disclose
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience (U); AstraZeneca (U); Boehringer Ingelheim (U); Pfizer (U); Roche (U)
Honoraria - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
L. E. Shepherd
No relevant relationships to disclose
M. N. Pollak
No relevant relationships to disclose